Results 111 to 120 of about 775,328 (297)

Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis [PDF]

, 2017
Importance: Numerous studies have evaluated the prognostic value of minimal residual disease (MRD) in patients with multiple myeloma (MM). Most studies were small and varied in terms of patient population, treatment, and MRD assessment methods. Objective:
Anderson, KC, Avet-Loiseau, H, Child, JA, Georgieva, A, Gregory, WM, Munshi, NC, Owen, RG, Rawstron, AC, Samur, MK, Sherrington, P, Thakurta, A   +10 more
core   +1 more source

Identification of residual leukemic cells by flow cytometry in childhood B-cell precursor acute lymphoblastic leukemia: verification of leukemic state by flow-sorting and molecular/cytogenetic methods

Haematologica, 2012
Reduction in minimal residual disease, measured by real-time quantitative PCR or flow cytometry, predicts prognosis in childhood B-cell precursor acute lymphoblastic leukemia.
Nina F. Øbro, Lars P. Ryder, Hans O. Madsen, Mette K. Andersen, Birgitte Lausen, Henrik Hasle, Kjeld Schmiegelow, Hanne V. Marquart   +7 more
doaj   +1 more source

A Phase I/II first-line study of R-CHOP plus B-cell receptor/NF-κB-double-targeting to molecularly assess therapy response [PDF]

, 2019
The ImbruVeRCHOP trial is an investigator-initiated, multicenter, single-arm, open label Phase I/II study for patients 61-80 years of age with newly diagnosed CD20+ diffuse large B-cell lymphoma and a higher risk profile (International Prognostic Index ...
Anagnostopoulos, Ioannis, Bittner, Aitomi, Denker, Sophy, Frick, Mareike, Hummel, Michael, Kase, Julia, Na, Il-Kang, Schmitt, Clemens A.   +7 more
core   +2 more sources

Gene rearrangement study for minimal residual disease monitoring in children with acute lymphocytic leukemia

Revista Brasileira de Hematologia e Hemoterapia, 2013
OBJECTIVE To detect markers for minimal residual disease monitoring based on conventional polymerase chain reaction for immunoglobulin, T-cell receptor rearrangements and the Sil-Tal1 deletion in patients with acute lymphocytic leukemia. METHODS Fifty-
Juliana Godoy Assumpcao, Francisco Danilo Ferreira Paula, Sandra Guerra Xavier, Mitiko Murao, Joaquim Caetano de Aguirre Neto, Alvaro Pimenta Dutra, Eduardo Ribeiro Lima, Benigna Maria de Oliveira, Marcos Borato Viana   +8 more
doaj   +1 more source

Predicting lung cancer recurrence from circulating tumour DNA. Commentary on 'Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution' [PDF]

, 2017
No abstract ...
Daniel J Murphy, HG Colt, J Mazieres, JC Wan, JP Pignon, K Suzawa, Kevin G Blyth, L Calman, M Jamal-Hanjani, M Schuler, TD Crabtree, WC Hanna   +11 more
core   +1 more source

A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia

Haematologica, 2019
A high proportion of patients with acute myeloid leukemia who achieve minimal residual disease negative status ultimately relapse because a fraction of pathological clones remains undetected by standard methods.
Esther Onecha, Maria Linares, Inmaculada Rapado, Yanira Ruiz-Heredia, Pilar Martinez-Sanchez, Teresa Cedena, Marta Pratcorona, Jaime Perez Oteyza, Pilar Herrera, Eva Barragan, Pau Montesinos, Jose Antonio Garcia Vela, Elena Magro, Eduardo Anguita, Angela Figuera, Rosalia Riaza, Pilar Martinez-Barranco, Beatriz Sanchez-Vega, Josep Nomdedeu, Miguel Gallardo, Joaquin Martinez-Lopez, Rosa Ayala   +21 more
doaj   +1 more source

Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force [PDF]

, 2013
Background: Therapeutic targets have been defined for diseases like diabetes, hypertension or rheumatoid arthritis and adhering to them has improved outcomes. Such targets are just emerging for spondyloarthritis (SpA). Objective: To define the treatment
Baraliakos, Xenofon, Betteridge, Neil, Braun, Jürgen, Burgos-Vargas, Ruben, Collantes-Estevez, Eduardo, de Wit, Martinus, Deodhar, Atul, Dougados, Maxime, Elewaut, Dirk, Emery, Paul, FitzGerald, Oliver, Gossec, Laure, Helliwell, Philip, Jongkees, Merryn, Kavanaugh, Arthur, Kvien, Tore K, Landewé, Robert, Luger, Thomas, Maccarone, Mara, Mease, Philip, Olivieri, Ignazio, Redlich, Kurt, Reveille, John, Ritchlin, Christopher, Rudwaleit, Martin, Schoels, Monika, Sieper, Joachim, Smolen, Josef S, Van den Bosch, Filip, van der Heijde, Désirée, Wei, James Cheng-Chung, Winthrop, Kevin   +31 more
core   +2 more sources

The CAPRA score versus sub-types of minimal residual disease to predict biochemical failure after external beam radiotherapy [PDF]

, 2020
Nigel P Murray, Sócrates Aedo, Cynthia Fuentealba, Eduardo Reyes, Aníbal Salazar, Eghon Guzmán, Shenda Orrego   +6 more
openalex   +1 more source

Treatment Strategy for Ultra-High-Risk Multiple Myelomas with Chromosomal Aberrations Considering Minimal Residual Disease Status and Bone Marrow Microenvironment [PDF]

, 2023
Kazuhito Suzuki, Shingo Yano
openalex   +1 more source

How and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European LeukaemiaNet

Haematologica, 2009
Resistance to therapeutic agents is a major factor in the failure of cancer treatments. In leukemia, the resistant cells remaining in the bone marrow and/or peripheral blood constitute minimal residual disease and are detectable by highly sensitive ...
Marie C. Béné, Jaspal S. Kaeda
doaj   +1 more source